Advertisement

The role of progesterone receptors in meningioma

  • Steven M. Grunberg
Part of the Cancer Treatment and Research book series (CTAR, volume 58)

Abstract

The recognition, description, and investigation of the role of hormone receptors, particularly progesterone receptors, in the growth of meningioma and the potential value of this information in the treatment of meningioma demonstrate a particularly rewarding interaction between the oncologist, the epidemiologist, the pathologist, the endocrinologist, and the neurosurgeon.Associations first described in case reports led to epidemiologic studies that confirmed these clinical impressions. Analysis of meningiomas by hormone receptor assay suggested a mechanism responsible for the clinical observations.These hormone receptor assays have recently been confirmed, in turn, by immunohistochemical studies. Appreciation of this mechanism has now resulted in clinical trials of hormonal manipulation for the control of unresectable meningioma.

Keywords

Estrogen Receptor Androgen Receptor Progesterone Receptor Medroxyprogesterone Acetate Meningioma Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Quest DO. Meningiomas: an update. Neurosurgery 3:219–225, 1978.PubMedCrossRefGoogle Scholar
  2. 2.
    Kepes JJ. Meningiomas-Biology, Pathology, and Differential Diagnosis. Masson Publishing, New York, 1982, pp. 17–19.Google Scholar
  3. 3.
    Cushing H and Eisenhardt L. Meningiomas arising from the tuberculum sellae with the syndrome of primary optic atrophy and bitemporal field defects combined with a normal sella turcica in a middle-aged person. Arch Ophthalmol 1:1–41, 1929.Google Scholar
  4. 4.
    Roelvink NCA, Kamphorst W, van Alphen HAM, and Rao R. Pregnancy-related primary brain and spinal tumors. Arch Neurol 44:209–215, 1987.PubMedGoogle Scholar
  5. 5.
    Weyand RD, MacCarty CS, and Wilson RB. The effect of pregnancy on intracranial meningiomas occurring about the optic chiasm. Surg Clin North Am 31:1225–1233, 1951.PubMedGoogle Scholar
  6. 6.
    Bickerstaff ER, Small JM, and Guest IA. The relapsing course of certain meningiomas in relation to pregnancy and menstruation. Neurol Neurosurg Psych 21:89–91, 1958.CrossRefGoogle Scholar
  7. 7.
    Michelsen JJ and New PFJ. Brain tumor and pregnancy. J Neurol Neurosurg Psych 32: 305–307, 1969.CrossRefGoogle Scholar
  8. 8.
    Manganiello PD, Meltz RC, and Andros GJ. Probable parasellar meningioma in a pregnant woman. Obstet Gynecol 53:43S–46S, 1979.PubMedGoogle Scholar
  9. 9.
    Goldberg M and Rapport ZH: Neurosurgical, obstetric and endocrine aspects of meningioma during pregnancy. Isr J Med Sci 23:825–828, 1987.PubMedGoogle Scholar
  10. 10.
    Benzel EC and Gelder FB. Correlation between sex hormone binding and peritumoral edema in intracranial meningiomas. Neurosurgery 23:169–174, 1988.PubMedCrossRefGoogle Scholar
  11. 11.
    Smith FP, Slavik M, and MacDonald JS. Association of breast cancer with meningioma. Report of two cases and review of the literature. Cancer 42:1992–1994, 1978.PubMedCrossRefGoogle Scholar
  12. 12.
    Mehta D, Khatib R, and Patel S. Carcinoma of the breast and meningioma. Association and management. Cancer 51:1937–1940, 1983.PubMedCrossRefGoogle Scholar
  13. 13.
    Miller RE. Breast cancer and meningioma. J Surg Oncol 31:182–183, 1986.PubMedCrossRefGoogle Scholar
  14. 14.
    Schoenberg BS, Christine BW, and Wisnant JP. Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 25:705–712, 1975.PubMedGoogle Scholar
  15. 15.
    Emry JK. The Association between Breast Cancer and Meningiomas. Master’s thesis (Biometry), University of Southern California, Los Angeles, California, 1984.Google Scholar
  16. 16.
    Donnell MS, Meyer GA, and Donegan WL. Estrogen-receptor protein in intracranial meningiomas. J Neurosurg 50:499–502, 1979.PubMedCrossRefGoogle Scholar
  17. 17.
    Schnegg J-F, Gomez F, LeMarchand-Beraud T, and de Tribolet N. Presence of sex steroid hormone receptors in meningioma tissue. Surg Neurol 15:415–418, 1981.PubMedCrossRefGoogle Scholar
  18. 18.
    Tilzer LL, Plapp FV, Evans JP, Stone D, and Alward K. Steroid receptor proteins in human meningiomas. Cancer 49:633–636, 1982.PubMedCrossRefGoogle Scholar
  19. 19.
    Yu Z-Y, Wrange O, Haglund B, Granholm L, and Gustafsson J-A. Estrogen and progestin receptors in intracranial meningiomas. J Steroid Biochem 16:451–456, 1982.PubMedCrossRefGoogle Scholar
  20. 20.
    Markwalder T-M, Zava DT, Goldhirsch A, and Markwalder RV. Estrogen and progesterone receptors in meningiomas in relation to clinical and pathologic features. Surg Neurol 20:42–47, 1983.PubMedCrossRefGoogle Scholar
  21. 21.
    Blankenstein MA, Blaauw G, Lamberts WJ, and Mulder E. Presence of progesterone receptors and absence of oestrogen receptors in human intracranial meningioma cytosols. Eur J Cancer Clin Oncol 19:363–370, 1983.CrossRefGoogle Scholar
  22. 22.
    Vaquero J, Marcos ML, Martinez R, and Bravo G. Estrogen- and progesterone-receptor proteins in intracranial tumors. Surg Neurol 19:11–13, 1983.PubMedCrossRefGoogle Scholar
  23. 23.
    Pertuiset BF, Moguilewsky M, Magdelenat H, Martin PM, Philibert D, and Poisson M. Sex steroid receptors in human meningioma and glioma. In: Progress in Cancer Research and Therapy, Vol. 31, F Bresciani, RJB King, ME Lippman, M Namer, J-P Raynaud (eds). Raven Press, New York, 1984, pp. 561–568.Google Scholar
  24. 24.
    Whittle IR, Foo MS, Besser M, and Vanderfield GK. Progesterone and oestrogen receptors in meningiomas: biochemical and clinicopathoiogical considerations. Aust NZ J Surg 54:325–330, 1984.CrossRefGoogle Scholar
  25. 25.
    Martuza RL, Miller DC, and MacLaughlin DT. Estrogen and progestin binding by cytosolic and nuclear fractions of human meningiomas. J Neurosurg 62:750–756, 1985.PubMedCrossRefGoogle Scholar
  26. 26.
    Courriere P, Tremoulet M, Eche N, and Armand J-P. Hormonal steroid receptors in intracranial tumours and their relevance in hormone therapy. Eur J Cancer Clin Oncol 21:711–714, 1985.PubMedCrossRefGoogle Scholar
  27. 27.
    Reubi JC, Maurer R, Klijn JGM, Stefanko SZ, Foekens JA, Blaauw G, Blankenstein MA, and Lamberts SWJ. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab 63:433–438, 1986.PubMedCrossRefGoogle Scholar
  28. 28.
    Ironside JW, Battersby RDE, Dangerfield VJM, Parsons MA, Timperley WR, and Underwood JCE. Cryostat section assay of oestrogen and progesterone receptors in meningiomas: a clinicopathoiogical study. J Clin Pathol 39:44–50, 1986.PubMedCrossRefGoogle Scholar
  29. 29.
    Grunberg SM, Daniels AM, Muensch H, Daniels JR, Bernstein L, Kortes V, and Weiss MH. Correlation of meningioma hormone receptor status with hormone sensitivity in a tumor stem cell assay. J Neurosurg 66:405–408, 1987.PubMedCrossRefGoogle Scholar
  30. 30.
    Punnonen R and Kuurne T. Estrogen and progestin receptors in intracranial tumors. Hormone Res 27:74–77, 1987.PubMedCrossRefGoogle Scholar
  31. 31.
    Whittle IR, Hawkins RA, and Miller JD. Sex hormone receptors in intracranial tumors and normal brain. Eur J Surg Oncol 13:303–307, 1987.PubMedGoogle Scholar
  32. 32.
    Lesch K-P, Schott W, Engl H-G, Gross S, and Thierauf P. Gonadal steroid receptors in meningiomas. J Neurol 234:328–333, 1987.PubMedCrossRefGoogle Scholar
  33. 33.
    Kornblum JA, Bay JW, and Gupta MK. Steroid receptors in human brain and spinal cord tumors. Neurosurgery 23:185–188, 1988.PubMedCrossRefGoogle Scholar
  34. 34.
    Halper J, Colvard DS, Scheithauer BW, Jiang N-S, Press MF, Graham ML, Riehl E, Laws ER Jr., and Spelsberg TC. Estrogen and progesterone receptors in meningiomas: comparison of nuclear binding, dextran-coated charcoal, and immunoperoxidase staining assays. Neurosurgery 25:546–553, 1989.PubMedCrossRefGoogle Scholar
  35. 35.
    Lee L-S, Chi C-W, Change T-J, Chou M-D, Liu H-C, and Liu T-Y. Steroid hormone receptors in meningiomas of Chinese patients. Neurosurgery 25:541–545, 1989.PubMedCrossRefGoogle Scholar
  36. 36.
    Schwartz MR, Randolph RL, Cech DA, Rose JE, and Panko WB. Steroid hormone binding macromolecules in meningiomas. Failure to meet criteria of specific receptors. Cancer 53:922–927, 1984.PubMedCrossRefGoogle Scholar
  37. 37.
    Horwitz KB, Koseki Y, and McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103:1742–1751, 1978.PubMedCrossRefGoogle Scholar
  38. 38.
    Horwitz KB, Mockus MB, and Lessey BA. Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell 28: 633–642, 1982.PubMedCrossRefGoogle Scholar
  39. 39.
    Blankenstein MA, Berns PMJJ, Blaauw G, Mulder E, and Thijssen JHH. Search for estrogen receptors in human meningioma tissue sections with a monoclonal antibody against the human estrogen receptor. Cancer Res 46:4268s–4270s, 1986.PubMedGoogle Scholar
  40. 40.
    Scatchard G. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51:660–672, 1949.CrossRefGoogle Scholar
  41. 41.
    Press MF and Greene GL. Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor. Endocrinology 122:1165–1175, 1988.PubMedCrossRefGoogle Scholar
  42. 42.
    Waelti ER and Markwalder T-M. Immunocytochemical evidence of progesterone receptors in human meningiomas. Surg Neurol 31:172–176, 1989.PubMedCrossRefGoogle Scholar
  43. 43.
    Blankenstein MA, van der Meulen-Dijk C, and Thijssen JHH. Assay of oestrogen and progestin receptors in human meningioma cytosols using immunological methods. Clin Chim Acta 165:189–195, 1987.PubMedCrossRefGoogle Scholar
  44. 44.
    Jay JR, MacLaughlin DT, Riley KR, and Martuza RL. Modulation of meningioma cell growth by sex steroid hormones in vitro. J Neurosurg 62:757–762, 1985.PubMedCrossRefGoogle Scholar
  45. 45.
    Olson JJ, Beck DW, Schlechte J, and Loh P-M. Hormonal manipulation of meningiomas in vitro. J Neurosurg 65:99–107, 1986.PubMedCrossRefGoogle Scholar
  46. 46.
    Maiuri F, Montagnani S, Gallicchio B, Carandente M, Lanza GG, and D’Andrea F. Oestrogen and progesterone sensitivity in cultured meningioma cells. Neurol Res 11:9–13, 1989.PubMedGoogle Scholar
  47. 47.
    Waelti ER and Markwalder T-M. Endocrine manipulation of meningiomas with medroxyprogesterone acetate. Effect of MPA on growth of primary meningioma cells in monolayer tissue culture. Surg Neurol 31:96–100, 1989.PubMedCrossRefGoogle Scholar
  48. 48.
    Markwalder T-M, Gerber HA, Waelti E, Schaffner T, and Markwalder RV. Hormonotherapy of meningiomas with medroxyprogesterone acetate. Immunohistochemical demonstration of the effect of medroxyprogesterone acetate on growth fractions of meningioma cells using the monoclonal antibody Ki-67. Surg Neurol 30:97–101, 1988.PubMedCrossRefGoogle Scholar
  49. 49.
    Bardon S, Vignon F, Chalbos D, and Rochefort H. RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. Clin Endocrinol Metab 50:692–697, 1985.Google Scholar
  50. 50.
    Olson JJ, Beck DW, Schlechte JA, and Loh P-M. Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice. J Neurosurg 66:584–587, 1987.PubMedCrossRefGoogle Scholar
  51. 51.
    Olson JJ, Beck DW, Maclndoe JW, and Loh P-M. Androgen receptors in meningiomas. Cancer 61:952–955, 1988.PubMedCrossRefGoogle Scholar
  52. 52.
    Reubi JC. Identification of somatostatin receptors in human tumors. Triangle 27:179–188, 1988.Google Scholar
  53. 53.
    Reubi JC, Horisberger U, Lang W, Koper JW, Braakman R, and Lamberts SWJ. Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol 134:337–344, 1989.PubMedGoogle Scholar
  54. 54.
    Kunert-Radek J, Stepien H, Radek A, and Pawlikowski M. Somatostatin suppression of meningioma cell proliferation in vitro. Acta Neurol Scand 75:434–436, 1987.PubMedCrossRefGoogle Scholar
  55. 55.
    Markwalder T-M, Seiler RW, and Zava DT. Antiestrogenic therapy of meningiomas-a pilot study. Surg Neurol 24:245–249, 1985.PubMedCrossRefGoogle Scholar
  56. 56.
    Magdelenat H, Pertuiset BF, Poisson M, and Philippon J. Steroid receptor status difference in recurrent intracranial meningioma and breast cancer in the same patient. J Neurooncol 4:155–157, 1986.PubMedCrossRefGoogle Scholar
  57. 57.
    Markwalder T-M, Waelti E, and Konig MP. Endocrine manipulation of meningiomas with medroxyprogesterone acetate. Effect of MPA on receptor status of meningioma cytosols. Surg Neurol 28:3–9, 1987.PubMedCrossRefGoogle Scholar
  58. 58.
    Jaaskelainen J, Laasonen E, Karkkainen J, Haltia M, and Troupp H. Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases. Acta Neurochir 80:35–41, 1986.CrossRefGoogle Scholar
  59. 59.
    Grunberg SM and Weiss MW. Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol 8:61–65, 1990.PubMedCrossRefGoogle Scholar
  60. 60.
    Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci L, and Stevenson LL. Treatment of unresectable meningiomas with the anti-progestational agent mifepristone. J Neurosurg 74:861–866, 1991.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston. 1992

Authors and Affiliations

  • Steven M. Grunberg

There are no affiliations available

Personalised recommendations